Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Omeros Corporation

< Previous 1 2 3 Next >
Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Reports Second Quarter 2025 Financial Results
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Announces Webcast Details for Annual Meeting of Shareholders
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Reports First Quarter 2025 Financial Results
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026
From Omeros Corporation
Via Business Wire
Tickers OMER
FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Provides Update on Progress Toward BLA Resubmission
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Reports Third Quarter 2024 Financial Results
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024
From Omeros Corporation
Via Business Wire
Tickers OMER
FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation Reports Second Quarter 2024 Financial Results
From Omeros Corporation
Via Business Wire
Tickers OMER
Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024
From Omeros Corporation
Via Business Wire
Tickers OMER
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.